US Edition
Published • loading... • Updated
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
- CStone Pharmaceuticals presented preclinical data for three proprietary ADCs, including CS5007, at the AACR Annual Meeting held from April 17 to 22, 2026.
- CS5007 targets EGFR and HER3 receptors to block nearly all oncogenic HER-family receptor complexes and inhibit tumor cell survival pathways.
- CS5007 demonstrated superior plasma stability in vitro compared to the DS-8201 benchmark and exerts potent, nanomolar-level, antigen-dependent cell-killing activity across multiple tumor types including NSCLC and breast cancer.
- CStone Pharmaceuticals plans to submit an Investigational New Drug application for CS5007 in the first half of 2026.
Insights by Ground AI
45 Articles
45 Articles
The Berkshire Eagle+44 Reposted by 44 other sources
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the…
Coverage Details
Total News Sources45
Leaning Left7Leaning Right6Center12Last UpdatedBias Distribution48% Center
Bias Distribution
- 48% of the sources are Center
48% Center
L 28%
C 48%
R 24%
Factuality
To view factuality data please Upgrade to Premium
